High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study.

摘要: Erythropoietin promotes nephroprotection in animal models of ischemia-reperfusion injury. Neorecormon® and Prevention Delayed Graft Function (Neo-PDGF) is a French open-label multicenter randomized study to evaluate the effect high doses epoetin beta (EPO-β) during first 2 weeks renal transplantation on function patients at risk for delayed graft (DGF). One hundred four were included study. Patients treatment group (A) received injections EPO-β (30.000 UI each), given before surgery 12 h, 7 days 14 posttransplantation. control (B) did not receive EPO-β. Immunosuppression induction with basiliximab maintenance therapy steroids, mycophenolate mofetil tacrolimus. At 1 month posttransplant, estimated glomerular filtration rate (MDRD formula) was 42.5 ± 19.0 mL/min 44.0 16.3 (p = ns). The frequency DGF similar both groups (32% vs. 38.8%; p No difference incidence serious adverse events observed. (ClinicalTrials.gov number, NCT00815867.)